American Pharmacy News
  • People
  • Innovation
  • Regulatory
  • Industry
  • Federal Issues
  • State Issues
  • Directory
  • People
  • Innovation
  • Regulatory
  • Industry
  • Federal Issues
  • State Issues
  • Directory
  • Home
  • »
  • Stories
  • »
  • 2017

AstraZeneca taps Biologics to distribute carcinoma drug

American Pharmacy News Reports | Jul 28, 2017
Patients diagnosed with advance bladder cancer often start receiving platinum-containing chemotherapy.

Biologics Inc., a McKesson Specialty Health oncology pharmacy services company, has been chosen by AstraZeneca to distribute Imfinzi. Read More »

Amgen and UCB release positive results for Evenity study

American Pharmacy News Reports | Jul 28, 2017
Patients given Evenity for 12 months followed by alendronate saw reductions in vertebral fracture incidents.

Amgen and UCB recently announced that their Evenity study, which analyzed the drug as a treatment for postmenopausal women with osteoporosis, met both primary endpoints and the secondary endpoint. Read More »

Therigy partners with EPI-W to expand research on specialty pharmacy outcomes

American Pharmacy News Reports | Jul 28, 2017
Therigy noted that EPI-Q brings more than 20 years of experience to the research table.

Therigy, a company that pioneered patient-focused specialty therapy management, recently announced a strategic partnership with EPI-Q Inc. to expand research on specialty pharmacy outcomes. Read More »

FDA approves Sanofi's Kevzara for rheumatoid arthritis treatment

American Pharmacy News Reports | Jul 30, 2017
Sanofi's CEO said rheumatoid arthritis patients continue to need new treatment options.

Sanofi and Regeneron Pharmaceuticals Inc. recently announced that Kevzara (sarilumab), a treatment for adult patients with moderately to severely active rheumatoid arthritis who have not responded well to one or more disease modifying antirheumatic drugs, has been approved by the U.S. Food and Drug Administration. Read More »

Good Neighbor Pharmacy network adds fee estimator tool

American Pharmacy News Reports | Jul 30, 2017
AmerisourceBergen strives to simplify industry challenges for independent pharmacists via its Good Neighbor Pharmacy initiative.

Pharmaceutical provider AmerisourceBergen recently unveiled the DIR Fee Estimator, its newest tool in conjunction with its nationwide Good Neighbor Pharmacy network, to streamline transactions between provider networks and pharmacy benefit managers by providing cost estimate ranges. Read More »

FDA clears first neonatal MRI device

American Pharmacy News Reports | Jul 31, 2017
The Embrace Neonatal MRI System is designed specifically for imaging of the neonatal head.

To better tend babies in the nation’s neonatal intensive care units, the first magnetic resonance imaging (MRI) device designed for newborns recently garnered U.S. Food and Drug Administration approval following thorough safety confirmation. Read More »

FDA accepts Amgen’s BLA for Aimovig (erenumab)

American Pharmacy News Reports | Jul 31, 2017
kind, according to the company: a monoclonal antibody that inhibits the calcitonin gene-related peptide receptor.  Data was gleaned from studies involving over 2,600 patients.

California-based Amgen recently obtained U.S. Food and Drug Administration (FDA) acceptance of its Biologics License Application (BLA) for Aimovig (erenumab), a product developed specifically to help victims of frequent migraine headaches. Read More »

Chinese officials accept study application for GBM treatment

American Pharmacy News Reports | Jul 31, 2017
The company will begin enrollment for the trial in the next few weeks at Sun Yat-sen University Cancer Center.

DelMar Pharmaceuticals' application for a Phase II study evaluating a treatment for newly diagnosed MGMT-unmethylated glioblastoma multiforme has been accepted by the Human Genetic Resources Administration of China. Read More »

Luminex Corp.'s c. difficile assay attains FDA clearance

American Pharmacy News Reports | Jul 31, 2017
C. difficile is an urgent threat as it is now the most common microbial cause of health care-associated infections in U.S. hospitals.

Luminex Corporation recently announced that its ARIES clostridium difficile (c. difficile) assay has been given U.S. Food and Drug Administration (FDA) clearance. Read More »

Health Canada to review Sunovion's schizophrenia treatment

American Pharmacy News Reports | Jul 31, 2017
Schizophrenia is a critical, often disabling brain disorder.

Sunovion Pharmaceuticals Inc. of Marlborough, Massachusetts recently gained approval for its supplemental new drug submission regarding Latuda (lurasidone HCI) — aimed at relieving adolescent schizophrenia — from Health Canada, potentially extending the treatment’s age range. Read More »

European agency approves Tocagen's treatment for high grade glioma

American Pharmacy News Reports | Aug 3, 2017
HGG is a common form of brain cancer that is highly aggressive.

Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, recently announced that its Toca 511 was awarded PRIME designation by the European Medicines Agency for treating high grade glioma patients. Read More »

Accord acquires rights to sell Custodiol HTK Solution

American Pharmacy News Reports | Aug 3, 2017
The acquisition gives Accord the rights to sell Custodiol HTK Solution.

Accord Healthcare has acquired Essential Pharmaceuticals, a New Jersey company that provides products, services and contributions to transplant medicine. Read More »

Merck launches Renflexis as biosimilar with FDA consent

American Pharmacy News Reports | Aug 3, 2017
Renflexis is a tumor necrosis factor (TNF) blocker and is indicated for the treatment of several digestive and autoimmune disorders.

New Jersey-based Merck recently introduced Renflexis (infliximab-abda) in the United States as a biosimilar of Remicade (infliximab) following its FDA approval last April for all eligible indications. Read More »

Lexicon and Ipsen's MAA for Xermelo given positive opinion by CHMP

American Pharmacy News Reports | Aug 3, 2017
The European Commission will now make a final decision on whether to approve the MAA for the drug.

Lexicon Pharmaceuticals Inc.'s Xermelo, a carcinoid syndrome diarrhea treatment created in collaboration with Ipsen, has been given a positive opinion for Marketing Authorization Application by the Committee for Medicinal Products for Human Use, the committee of the European Medicines Agency responsible for human medicines. Read More »

Thermo Fisher adds mini implant line to its drug implant development line

American Pharmacy News Reports | Aug 3, 2017
Pharmaceutical manufacturers are seeking fast, reliable solutions for continuous production of novel drug delivery systems.

Thermo Fisher Scientific Inc. recently announced the availability of a fully integrated solution for polymer-based drug implant development and production using hot melt extrusion (HME). Read More »

Eisai's supplemental application for Fycompa CIII accepted

American Pharmacy News Reports | Aug 3, 2017
After first being approved for adjunctive use in POS in 2012, Fycompa went on to receive approval in 55 countries.

Eisai Inc.'s supplemental New Drug Application for Fycompa CIII has been accepted by the U.S. Food and Drug Administration. Read More »

Pfizer's Avastin biosimilar meets primary endpoint in study

American Pharmacy News Reports | Aug 4, 2017
PF-06439535, which Pfizer is developing as a potential biosimilar to Avastin, met its primary objective.

Pfizer Inc. recently announced positive results for its Reflections B7391003 study, which evaluated the safety and efficacy of PF-06439535 as compared to Avastin (bevacizumab). Read More »

Gilteritinib gains orphan-drug status to combat AML

American Pharmacy News Reports | Aug 4, 2017
Gilteritinib works by inhibiting certain receptors involved in cancer cell growth.

Because acute myeloid leukemia (AML) impacts relatively few individuals nationwide, gilteritinib — an anti-cancer medication developed by Tokyo-based Astellas Pharma Inc. — recently attained orphan-drug designation from the U.S. Food and Drug Administration. Read More »

EnvisionRx receives renewed accreditation from URAC

American Pharmacy News Reports | Aug 4, 2017
EnvisionRx has URAC accreditation for drug therapy management.

EnvisionRx, a pharmacy benefit manager (PBM) and division of EnvisionRxOptions, a wholly owned subsidiary of Rite Aid Corporation, recently announced that the health care accrediting organization URAC renewed the company’s accreditation for pharmacy benefit management. Read More »

Vizient releases Drug Price Forecast for 2018

Mark Iandolo | Aug 6, 2017
Health systems should see a 7.61 percent average increase in price on pharmaceutical purchases in 2018.

Vizient Inc. recently released its July 2017 Drug Price Forecast, which provides pharmacy leaders and health system executives with insights on pricing and practice changes throughout the pharmaceutical industry. Read More »

  • «
  • 1
  • 2
  • ...
  • 30
  • 31
  • 32 (current)
  • 33
  • 34
  • 35
  • 36
  • 37
  • »
Trending

 B. Douglas Hoey CEO

NCPA urges government action on pharmacy benefit managers' practices

John Kirtley Executive Director at Arkansas State Board of Pharmacy

Women's health block party to launch National Women's Health Month at Arkansas State Capitol

John Kirtley Executive Director at Arkansas State Board of Pharmacy

Arkansas Health Department extends hours for REAL ID birth certificate requests

 B. Douglas Hoey CEO

NCPA releases new "Show Me" episodes about maternal vaccination programs

Copyright © 2025 American Pharmacy News. All Rights Reserved.

  • About
  • Contact
  • Privacy Policy
  • Terms of Service

Alerts Sign-up